Abstract:Abstract Background The presence of the HLA-DQA1*05 allele has been related to a loss of early secondary response, which could have clinical implications when choosing the first-line biological drug. Although its usefulness as a response predictor variant is not yet clearly established, the determination of polymorphism is common in clinical practice. Methods The objective of this study is to determine if there is an association between the presence of HLA-DQA1*05 and the loss of response in the short-medium term in the clinical practice of a real cohort. A retrospective cohort study has been carried out including adult patients with Crohn's Disease (CD), ulcerative colitis (UC) and indeterminate colitis (IC) who have received anti-TNF treatment with Infliximab (IFX) and Adalimumab (ADA) with a period of follow-up from 6 to 48 months. Results A total of 102 patients were included (73.52% CD- 75; 25.5% UC- 26; 0.98% IC- 1), of which 54.9% were men (56) and 45.1% were women (46), with a median age of 45 years (IQR 18-83). No statistically significant differences were observed between the HLA carrier and non-HLA carrier groups in age, sex, tobacco consumption, or type of inflammatory bowel disease. No differences were also observed between the location or severity of the disease. From the group of patients treated with Infliximab: • IFX at 6 months: a total of 52 patients were analyzed. Treatment was suspended in 6 patients (11.54%). • IFX at 18 months: a total of 35 patients were analyzed.Treatment was suspended in 4 patients (11.43%). • IFX at 48 months: a total of 26 patients were analyzed. Treatment was suspended in 7 patients (26.92%). From the group of patients treated with Adalimumab: • ADA at 6 months: a total of 50 patients were analyzed. Treatment was suspended in 6 patients (12%). • ADA at 18 months: a total of 31 patients were analyzed. Treatment was suspended in 1 patient (3.22%). • ADA at 48 months: a total of 22 patients were analyzed. Treatment was suspended in 3 patients (13.64%). Therefore, no statistically significant differences were observed in the loss of anti-TNF response between the HLA-DQA1*05 carrier and non-carrier groups for IFX and ADA at 6, 18 or 48 months. Nor were any differences found in the loss of response depending on the type of inflammatory bowel disease that the patients suffered from (CD or UC). Conclusion In this Spanish cohort from real clinical practice, the presence of the HLA-DQA1*05 allele in patients with inflammatory bowel disease does not influence the loss of response to anti-TNF treatment in the first 48 months of follow-up. However, more studies with larger samples are necessary to determine the usefulness of the polymorphism in clinical practice and establish its possible predictive implication.

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease

P897 The association of HLA-DQA1*05 carriage with immunogenicity to anti-tumour necrosis factor therapy and drug persistence in Asian patients with inflammatory bowel disease

P586 Influence of HLA-DQA1∗05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice

P918 Can we rely on HLA to predict resistance to biological therapy in Inflammatory Bowel Disease patients?

OP37 Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU

HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn’s Disease Studies

HLA-DQA1*05 associates with anti-TNF immunogenicity and low adalimumab trough concentrations in inflammatory bowel disease patients from the SERENE UC and CD studies

Does HLA‐DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small‐bowel Crohn's disease?

P1070 Utilization of HLA-DQA1*05 haplotype testing in routine clinical practice to stratify advanced therapies: A prospective pilot study

HLA DQA105 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA105 and Pediatric Crohn's Disease

P807 HLA type impact on immunization and efficacy of ustekinumab in IBD patients: a multicenter study

HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease

HLA-DQA1*05 correlates with increased risk of anti-drug antibody development and reduced response to infliximab in Chinese patients with Crohn’s disease

P337 Proactive therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome and persistence of treatment

N31 HLA-DQA1*05 detection in saliva, an effective alternative in the monitoring and control of patients with Inflammatory Bowel Disease

Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.

The Association Between HLA-DQB1 Polymorphism and Antituberculosis Drug-Induced Liver Injury: a Case-Control Study.

P251 Proactive Therapeutic drug monitoring of Infliximab, but not HLA-DQA1*05, predicts clinical outcome in inflammatory bowel disease

P668 Dashboard-guided anti-TNF induction as an effective proactive strategy in Inflammatory Bowel Disease's treatment

S1413 Impact of Race on Clinical Outcomes in IBD Patients on Anti-TNF Monotherapy and Anti-TNF Combination Therapy With Immunomodulators: A Propensity-Matched Cohort Study